Protagenic Therapeutics (PTIX)

US · Healthcare · Biotechnology

$0.83-4.71%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Net profit

$-963,616

EPS

$-0.47

Market cap

$1.9M

Forward P/E

0.0

P/B

3.35

Book value

$0.95

EPS (TTM)

$-13.13

52-week high

$4.55

52-week low

$0.13

50-day MA

$0.44

200-day MA

$0.70

Beta

0.38

Analysts rate Protagenic Therapeutics a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $4.00.

Insiders

6.20%

Institutions

4.64%

Fund	Stake
DRW Securities, LLC	2.31%
United Financial Planning Group LLC	0.00%
Morgan Stanley - Brokerage Accounts	0.00%
Geode Capital Management, LLC	0.00%
Tower Research Capital LLC	0.00%
HARBOR INVESTMENT ADVISORY, LLC	0.00%
Advisor Group Holdings, Inc.	0.00%
CoreCap Advisors, LLC	0.00%

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Protagenic Therapeutics — free to start.

Data updated 2026-09-18.